Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "biochemical"

27 News Found

Ritesh Jain appointed CFO of Krebs Biochemicals and Industries
People | February 04, 2023

Ritesh Jain appointed CFO of Krebs Biochemicals and Industries

He is a Chartered Accountant with more than 19 years of extensive experience


Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
Drug Approval | June 01, 2026

Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers


Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling
News | January 03, 2026

Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling

Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols


Zeon Corporation to acquire Ushio’s microfluidics biz
News | December 27, 2025

Zeon Corporation to acquire Ushio’s microfluidics biz

Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology


UPM unveils world’s first carbon-negative, fully recyclable black pigment
Packaging | December 13, 2025

UPM unveils world’s first carbon-negative, fully recyclable black pigment

The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black


Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
Clinical Trials | December 07, 2025

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development


Enzalutamide leads to 40% lower risk of death in prostate cancer
Clinical Trials | October 22, 2025

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting


Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries
Opinion | July 28, 2025

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production


Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
News | July 11, 2025

Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting

Xtandi is approved in over 80 countries, including the U.S., EU, and Japan


Lucas Meyer Cosmetics by Clariant to launch honey-based skin repair solution ‘Melicica’
News | March 05, 2025

Lucas Meyer Cosmetics by Clariant to launch honey-based skin repair solution ‘Melicica’

Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care